Home › Samsung merger to drive growth in biopharmaceutical business
 

Keywords :   


Samsung merger to drive growth in biopharmaceutical business

2015-07-20 13:41:08| Electronics - Topix.net

Boosted by the successful merger of Samsung C&T and Cheil Industries last week, Samsung Group is geared to step up its efforts to expand and develop its biopharmaceutical business, seen by the group as a future growth engine. The $8 billion merger has tightened the group's grip on Samsung BioLogics, the conglomerate's biopharmaceutical business unit.

Tags: business drive growth samsung

Category:Electronics and Electrical

Latest from this category

All news
»
28.09Atlantic Tropical Weather Outlook
28.09Eastern North Pacific Tropical Weather Outlook
27.09Washington Corner | September 2024
27.09Hurricane Isaac Graphics
27.09Remnants of John Graphics
27.09Remnants of John Forecast Discussion Number 20
27.09Remnants of John Wind Speed Probabilities Number 20
27.09Remnants of John Public Advisory Number 20
More »